SanBio Co (TSE:4592) Research & Development: 円2,635.71 Mil (TTM As of Jan. 2026)


TSE:4592 SanBio Co Ltd TSE:4592
22 GF Score
Price 円997.00
! 1 Warning Sign
View Full Analysis

What is SanBio Co Research & Development?

SanBio Co TSE:4592 +4.95% 22 Research & Development is 円2,635.71 Mil as of Jan. 2026. GuruFocus rates TSE:4592 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. SanBio Co's Research & Development for the three months ended in Jan. 2026 was 円757.98 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jan. 2026 was 円2,635.71 Mil.

SanBio Co  (TSE:4592) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

SanBio Co Research & Development Related Terms

SanBio Co Research & Development Historical Data

* Premium members only.

The historical data trend for SanBio Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SanBio Co Research & Development Chart

SanBio Co Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,955.39 6,118.13 2,849.59 2,357.97 2,678.09

SanBio Co Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 723.14 623.63 573.34 757.98 680.76
TSE:4592
22GF Score
SanBio Co Ltd TSE:4592
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SanBio Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円2,635.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円2,635.71 Mil mean?
SanBio Co (TSE:4592) has a Research & Development of 円2,635.71 Mil as of Jan. 2026. Research and development expense is the total cost for research and development activities. View historical data on SanBio Co and its competitors.
Is SanBio Co's Research & Development too high?
SanBio Co's current Research & Development is 円2,635.71 Mil. Overall, SanBio Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does SanBio Co's Research & Development compare to VRTX and REGN?
SanBio Co's Research & Development of 円2,635.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on SanBio Co and its competitors. SanBio Co's current Research & Development is 円2,635.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SanBio Co stock overvalued right now?
SanBio Co (TSE:4592) has a current Research & Development of 円2,635.71 Mil. The current Research & Development is 円2,635.71 Mil. SanBio Co's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For SanBio Co (TSE:4592), the current Research & Development is 円2,635.71 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SanBio Co Business Description

Address 8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
22GF Score

Get the complete analysis for TSE:4592

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円997.00
Price